Increased Moxifloxacin Utilization Associated with an Unrestricted Addition to a Drug Reimbursement Formulary: A Population-Based Analysis | Zendy

Alissa Wright | Zendy; Fawziah Marra | Zendy; Mei Chong | Zendy; Catharine Chambers | Zendy; William Bowie | Zendy; David M. Patrick | Zendy

Open Access

Increased Moxifloxacin Utilization Associated with an Unrestricted Addition to a Drug Reimbursement Formulary: A Population-Based Analysis

Author(s) -

Alissa Wright,

Fawziah Marra,

Mei Chong,

Catharine Chambers,

William Bowie,

David M. Patrick

Publication year - 2014

Publication title -

canadian journal of infectious diseases and medical microbiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.634

H-Index - 38

eISSN - 1918-1493

pISSN - 1712-9532

DOI - 10.1155/2014/243014

Subject(s) - formulary , moxifloxacin , medicine , medical prescription , guideline , reimbursement , pediatrics , population , defined daily dose , drug utilization review , diagnosis code , emergency medicine , antibiotics , family medicine , health care , environmental health , pharmacology , pathology , microbiology and biotechnology , economics , biology , economic growth

To determine whether utilization of moxifloxacin, a broad-spectrum fluoroquinolone antibiotic, has changed since its addition to the British Columbia provincial formulary in 2009 and to determine whether utilization was guideline concordant.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research